Foghorn Therapeutics Files 8-K for Security Holder Vote
Ticker: FHTX · Form: 8-K · Filed: Jun 17, 2025 · CIK: 1822462
| Field | Detail |
|---|---|
| Company | Foghorn Therapeutics Inc. (FHTX) |
| Form Type | 8-K |
| Filed Date | Jun 17, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, shareholder-vote
Related Tickers: FHTX
TL;DR
Foghorn Therapeutics is calling for a shareholder vote on June 17, 2025. Details to follow.
AI Summary
On June 17, 2025, Foghorn Therapeutics Inc. filed an 8-K report to announce a submission of matters to a vote of its security holders. The filing does not disclose the specific matters to be voted on, but it indicates that a vote will take place.
Why It Matters
This filing signals that Foghorn Therapeutics is preparing for a shareholder vote, which could involve significant corporate decisions or changes.
Risk Assessment
Risk Level: medium — While the filing itself is procedural, the matters to be voted on could represent significant corporate events or changes that carry inherent risks.
Key Players & Entities
- Foghorn Therapeutics Inc. (company) — Registrant
- June 17, 2025 (date) — Date of earliest event reported
FAQ
What specific matters will be submitted to a vote of Foghorn Therapeutics' security holders?
The filing does not specify the exact matters to be submitted for a vote, only that such a submission is occurring.
When was the earliest event reported in this 8-K filing?
The earliest event reported is dated June 17, 2025.
What is the principal executive office address for Foghorn Therapeutics Inc.?
The principal executive offices are located at 500 Technology Square, Ste 700, Cambridge, MA 02139.
What is the SEC file number for Foghorn Therapeutics Inc.?
The SEC file number for Foghorn Therapeutics Inc. is 001-39634.
What is the fiscal year end for Foghorn Therapeutics Inc.?
The fiscal year end for Foghorn Therapeutics Inc. is December 31.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on June 17, 2025 regarding Foghorn Therapeutics Inc. (FHTX).